- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Jounce Therapeutics is a biotechnology business based in the US. Jounce Therapeutics shares (JNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Jounce Therapeutics employs 141 staff and has a trailing 12-month revenue of around $82 million.
Our top picks for where to buy Jounce Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Jounce Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – JNCE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Jounce Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Jounce Therapeutics stock price (NASDAQ: JNCE)
Use our graph to track the performance of JNCE stocks over time.Jounce Therapeutics shares at a glance
Information last updated 2024-06-30.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $1.64 |
| 200-day moving average | $1.93 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.96 |
Is it a good time to buy Jounce Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Jounce Therapeutics financials
| Revenue TTM | $82 million |
|---|---|
| Gross profit TTM | $27.2 million |
| Return on assets TTM | -14.04% |
| Return on equity TTM | -25.03% |
| Profit margin | -62.1% |
| Book value | $3.54 |
| Market Capitalization | $101.6 million |
TTM: trailing 12 months
Jounce Therapeutics share dividends
We're not expecting Jounce Therapeutics to pay a dividend over the next 12 months.
Jounce Therapeutics share price volatility
Over the last 12 months, Jounce Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jounce Therapeutics's is 0.7512. This would suggest that Jounce Therapeutics's shares are less volatile than average (for this exchange).
Jounce Therapeutics overview
Jounce Therapeutics, Inc. , a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What percentage of Jounce Therapeutics is owned by insiders or institutions?Currently 15.99% of Jounce Therapeutics shares are held by insiders and 85.331% by institutions. How many people work for Jounce Therapeutics?
Latest data suggests 141 work at Jounce Therapeutics. When does the fiscal year end for Jounce Therapeutics?
Jounce Therapeutics's fiscal year ends in December. Where is Jounce Therapeutics based?
Jounce Therapeutics's address is: 780 Memorial Drive, Cambridge, MA, United States, 02139 What is Jounce Therapeutics's ISIN number?
Jounce Therapeutics's international securities identification number is: US4811161011 What is Jounce Therapeutics's CUSIP number?
Jounce Therapeutics's Committee on Uniform Securities Identification Procedures number is: 481116101
More resources on Finder
More guides on Finder
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Ask a question